WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat ...
The MarketWatch News Department was not involved in the creation of this content. -- Collaboration with Blood Cancer United(R) in its Beat AML(R) Master Clinical Trial -- -- AVEO's ficlatuzumab ...
– Promising clinical activity and deep responses observed with 67% (29/43) CR rate, 88% (38/43) ORR, and 100% (37/37) MRD negativity among responders – – Enrollment underway in pivotal Ph 3 EVOLVE-2 ...
- 96% CRc (23 of 24 pts) observed in BEAT AML trial exploring revumenib in combination with venetoclax/azacitidine in newly diagnosed mNPM1 or KMT2Ar AML - - 52% CRc (14 of 27 pts) observed in AUGMENT ...
The Beat AML Master Trial found high remission rates and promising safety with triplet therapy in patients with acute myeloid leukemia (AML), according to Ashley Yocum, PhD. At the 30th European ...
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) is one of the best biotech stocks to invest in now. On June 12, Syndax Pharmaceuticals announced that data from the BEAT AML trial involving revumenib were ...
The Beat AML ® Master Clinical Trial is the first collaborative precision medicine clinical trial in a blood cancer. Launched by The Leukemia & Lymphoma Society—now Blood Cancer United—in 2016, the ...
Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia ...
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Arguably, we already are doing at least ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results